- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00113074
Preventing Weight Gain and Controlling Blood Pressure During Smoking Cessation in Hypertensive Smokers
Blood Pressure Control in Hypertensive Smokers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
BACKGROUND:
High blood pressure (BP), or hypertension, is a major risk factor for cardiovascular morbidity and mortality. Hypertension is associated with an elevated risk for several cardiovascular complications, including coronary heart disease, peripheral vascular disease, congestive heart failure, and stroke, as well as an increased risk for renal disease. Although there have been significant advances in the detection and treatment of high BP, approximately one in four adults in the United States is hypertensive. Cigarette smoking accounts for more than 400,000 premature deaths each year in this country alone, making it the leading cause of morbidity and mortality. Evidence from several epidemiological studies has demonstrated that, at any level of BP, smoking substantially increases the risk for all cardiovascular complications associated with hypertension. While cigarette smoking and hypertension both increase the risk of cardiovascular disease, these two risk factors act synergistically to produce a greater risk than their combined independent effects. Despite the considerable health risks, smoking among people with hypertension is very common, with a prevalence approaching that observed among those with normal BP. Unfortunately, although quitting smoking is especially important for patients with high BP, smoking cessation produces a nontrivial weight gain, averaging 5 kg, which may exacerbate hypertension in many patients with the disorder. Several studies have documented significant elevations in BP following smoking cessation, as well as increases in the prevalence of hypertension after quitting smoking. As such, it is important to develop effective interventions that assist in quitting smoking and preventing weight gain.
DESIGN NARRATIVE:
The objective of the trial is to recruit 750 smokers with Stage 1 hypertension or prehypertension (based on JNC VII criteria). The trial will provide all participants with a brief, validated, combined behavioral and pharmacologic smoking cessation intervention. Additionally, the study will randomly assign participants who are abstinent from smoking upon completing the cessation intervention to either a 12-week weight management and BP control program or self-help materials targeting lifestyle modification. The primary endpoint is change in BP among quit smokers at a one-year follow-up. Secondary endpoints include changes in body weight, dietary intake, urinary sodium excretion, physical activity, and relapse to smoking. Exploratory endpoints include changes in hypertensive status (e.g., movement from prehypertensive to hypertensive by JNC VII criteria) and changes in BP medication status. This is a multi-site clinical trial, with study locations in Rochester, Minnesota, and Iowa City, IA. The Rochester, MN site is currently closed for recruitment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States
- University of Iowa, Carver College of Medicine, Department of Internal Medicine, Division of General Internal Medicine
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Smoke at least 5 cigarettes/day (or have quit within the last 6 weeks to enter the study for the weight gain prevention and BP control interventions)
- Pre-hypertensive or Stage I hypertension (systolic BP from 120 to 159 and/or diastolic BP from 80 to 99 mm Hg). Antihypertensive medications are not criteria for exclusion provided that BP is not over 160/100 mm Hg)
- Access to a telephone
Exclusion Criteria:
- History of unstable cardiovascular disease, including myocardial infarction, stroke, and unstable angina within three months of study start
- Coronary artery bypass grafting or angioplasty/stent within three months of study start
- Cardiac dysrhythmia treated with anti-arrhythmia medication, except stable atrial fibrillation
- Untreated hyperthyroidism or pheochromocytoma
- History of congestive heart failure (NYHA Class III or IV)
- ECG evidence of 2nd or 3rd degree atrioventricular block
- Uncontrolled or Stage II Hypertension as defined as BP consistently above 160/100 mm Hg
- History of severe liver or kidney failure
- Current substance abuse (includes alcohol use in excess of 21 drinks a week)
- Presence of an unstable psychiatric condition
- Severe chronic obstructive pulmonary disease
- Symptomatic peripheral vascular disease
- Pulmonary hypertension with shortness of breath
- Congenital or valvular heart disease with shortness of breath
- Current use of a medication that may interfere with primary study endpoints or that may increase the risk of side effects from study medication that cannot be discontinued
- Pregnant or plans to become pregnant within the next year
- Planning to move out of the area or travel extensively during the intervention
- Any medical condition that would preclude any additional changes in diet
- Unable to further modify physical activity routine
- Cannot engage in moderate intensity exercise (e.g., walking)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Weight management and BP control program
|
Nicotine replacement therapy program
Diet program
|
Active Comparator: 2
Self-help materials targeting lifestyle modification
|
Nicotine replacement therapy program
Diet program
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in BP among people who have quit smoking
Time Frame: Measured at Year 1
|
Measured at Year 1
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in body weight
Time Frame: Measured at Year 1
|
Measured at Year 1
|
Dietary intake
Time Frame: Measured at Year 1
|
Measured at Year 1
|
Urinary sodium excretion
Time Frame: Measured at Year 1
|
Measured at Year 1
|
Physical activity
Time Frame: Measured at Year 1
|
Measured at Year 1
|
Relapse to smoking
Time Frame: Measured at Year 1
|
Measured at Year 1
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mark W. Vander Weg, PhD, University of Iowa, Carver College of Medicine, Department of Internal Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 179
- R01HL072782 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Diseases
-
Baker Heart and Diabetes InstitutePrincess Alexandra Hospital, Brisbane, Australia; Royal Perth Hospital; Alice... and other collaboratorsRecruitingHeart Failure | Valve Heart DiseaseAustralia
-
Medical University of ViennaUnknownHeart Diseases | Heart Failure | Valvular Heart DiseaseAustria
-
Centre Chirurgical Marie LannelongueActive, not recruitingValvular Heart Disease | Valve Disease, Heart
-
Aristotle University Of ThessalonikiRecruitingCardiovascular Diseases | Heart Failure | Valvular Heart Disease | Biochemical DysfunctionGreece
-
Abiomed Inc.RecruitingHeart Diseases | Acute Decompensated Heart Failure | Congestive Heart Failure | Acute Heart FailureUnited States
-
Kathirvel SubramaniamUniversity of Maryland, Baltimore; CSL BehringRecruitingHeart Failure,Congestive | Heart Disease End StageUnited States
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
University of MichiganTerminatedDiastolic Heart Failure | Hypertensive Heart DiseaseUnited States
-
National Taiwan University HospitalRecruitingValve Heart DiseaseTaiwan
Clinical Trials on Nicotine Replacement Therapy
-
University of Kansas Medical CenterPatient-Centered Outcomes Research InstituteCompletedSmoking | Pulmonary Disease, Chronic Obstructive | Tobacco Use DisorderUnited States
-
NYU Langone HealthNational Cancer Institute (NCI)Recruiting
-
Centre for Addiction and Mental HealthCanadian Cancer Society (CCS)RecruitingSmoking Cessation | Tobacco Smoking | Substance Use Disorders | Nicotine Dependence | Nicotine Use DisorderCanada
-
Mark Vander WegIowa City VA Health Care SystemUnknownNicotine Dependence | Smokeless TobaccoUnited States
-
Rutgers, The State University of New JerseyCompleted
-
Fred Hutchinson Cancer CenterPalo Alto Veterans Institute for Research; Bedford Research Corporation, Inc.; Jefferson Center, Community Mental Health Clinic and other collaboratorsCompletedSmoking | Bipolar DisorderUnited States
-
University of VermontActive, not recruitingNicotine Addiction | Quitting Smoking | E-Cig UseUnited States
-
University of VermontCompletedTobacco Use DisorderUnited States
-
University of MonastirCompletedSmoking | Recurrence | Acute Coronary SyndromeTunisia
-
Johns Hopkins UniversityNational Cancer Institute (NCI); New York University; Colorado State University; Perinatal HIV Research Unit of the University of the WitswatersrandRecruitingSmoking Cessation | HIV | Comorbidities and Coexisting ConditionsSouth Africa